Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomized controlled trial.

Louis E. et al (2022 Jan), Withdrawal of infliximab or anti-metabolite therapy in Crohn’s Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE), Journal of Crohn’s and Colitis, Volume 16, Issue Supplement_1, Page i001.
DOI: 10.1016/s2468-1253(22)00385-5

For more information: BIOCYCLE website: biocycle-project.eu EU reference: grant agreement No 633168 – BIOCYCLE (PHC-13-2014).

12-Withdrawal of infliximab or concomitant immunosuppressant therapy-Lancet 2023